Lupin gets tentative nod for Rivaroxaban Tablets

24 Jan 2024 Evaluate

Lupin has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Rivaroxaban Tablets USP, 2.5 mg, 10 mg, 15 mg, and 20 mg, to market a generic equivalent of Xarelto Tablets, 2.5 mg, 10 mg, 15 mg, and 20 mg, of Janssen Pharmaceuticals, Inc. This product will be manufactured at Lupin’s Pithampur facility in India.

Rivaroxaban Tablets USP (RLD Xarelto) had estimated annual sales of $8,249 million in the U.S. (IQVIA MAT November 2023). 

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2085.00 -27.00 (-1.28%)
01-Jan-2026 10:29 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1712.65
Dr. Reddys Lab 1253.05
Cipla 1503.00
Zydus Lifesciences 910.20
Lupin 2085.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×